Novo Nordisk's amylin analog drug CagriSema is expected to launch early next year, with new data showing it can reduce "food noise."
Novo Nordisk's amylin drug CagriSema is expected to launch early next year, with the standalone cagrilintide and high-dose CagriSema anticipated in 2028. New data released by Novo Nordisk this week showed that CagriSema not only aids in weight loss but also reduces "food noise" (persistent thoughts about food) and improves organ and bone health. It also alters the brain's response to high-calorie foods in regions associated with craving, pleasure, and self-control. Novo Nordisk is also developing amycretin, a drug that simultaneously mimics the effects of GLP-1 and amylin.
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
Disclaimer: This content reflects the author's personal views only and does not constitute investment advice.
24H Trending
-
1
US airlines, Microsoft, banks, the NSA, and Apple have suffered consecutive outages, with varying causes and recovery progress
-
2
JPMorgan Chase: ConvaTec Group’s earnings update is expected to dispel market concerns over achieving its 2026 guidance
-
3
UBS expects the renminbi to strengthen to 6.25 per US dollar by the end of 2027.
-
4
White House: Trump Announces Over $17 Billion in Commercial Deals and Strategic Investments During Philippines Visit and ASEAN Summit
-
5
Medline Shareholders Raise $2.1 Billion via Share Offering, with Blackstone and Carlyle Participating
-
6
Bloomberg: U.S. Treasury prices edged up for a third consecutive day, supported by cooling risk appetite
-
7
UKMTO via Peninsula: Oil tanker attacked and catches fire 13 nm north of Khasab; fire extinguished, 1 person still missing
-
8
Korean Media: Daewoo E&C discloses delivery of immersed tube tunnel for Al Faw Grand Port to Iraq
-
9
Bloomberg: Indian Tax Officials Considering Proposal to Raise Stock Derivatives Tax and Lower Stock Transaction Tax
-
10
CoinDesk: Crypto Basis Trade Yields Near Treasuries, Talos Report Says
Markets Today
Recommended Reading


